市場調査レポート
商品コード
1462304
ネムバロイキンアルファの市場規模、予測、新薬の考察(2032年)Nemvaleukin alfa Market Size, Forecast, and Emerging Insight - 2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
ネムバロイキンアルファの市場規模、予測、新薬の考察(2032年) |
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 30 Pages
納期: 2~10営業日
|
ネムバロイキンアルファ(旧ALKS 4230)は、頭頸部がん、小細胞肺がん、卵巣がん、卵管がんなどの固形がんの治療薬としてAlkermesが開発中のインターロイキン2受容体作動薬です。この薬剤は修飾IL-2と高親和性IL-2α受容体鎖からなる融合タンパク質です。この組み合わせは、腫瘍を破壊する免疫細胞を増殖させる一方、中間親和性のIL-2レセプター複合体に優先的に結合することで免疫抑制細胞を活性化しないように設計されています。この薬剤の選択性は、IL-2療法の抗腫瘍効果を高めながら、その制限を緩和することを意図しています。
現在、プラチナ製剤抵抗性卵巣がんの治療薬としてフェーズ3臨床試験(ARTISTRY-7)が進行中であり、2025年12月までに完了する見込みです。
当レポートでは、主要7市場(米国・ドイツ・フランス・イタリア・スペイン・英国・日本)における卵巣がん向けネムバロイキンアルファについて調査分析し、作用機序、用法と用量、研究開発活動についての考察、収益の予測などを提供しています。
"Nemvaleukin alfa Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about nemvaleukin alfa for ovarian cancer in the seven major markets. A detailed picture of the nemvaleukin alfa for ovarian cancer in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the nemvaleukin alfa for ovarian cancer. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the nemvaleukin alfa market forecast analysis for ovarian cancer in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ovarian cancer.
Nemvaleukin alfa (previously known as ALKS 4230) is an interleukin-2 receptor agonist being developed by Alkermes for the treatment of solid tumors, including head and neck cancer, small cell lung cancer, ovarian cancer, fallopian tube cancer, and others. It is a fusion protein consisting of modified IL-2 and the high-affinity IL-2 alpha receptor chain. This combination is designed to expand tumor-destroying immune cells while not activating immunosuppressive cells by preferentially binding to the intermediate-affinity IL-2 receptor complex. The agent's selectivity is meant to mitigate limitations while boosting the anti-tumor effects of IL-2 therapy.
It is currently being investigated in Phase III clinical trial (ARTISTRY-7) for the potential treatment of Platinum-resistant Ovarian Cancer that is estimated to be completed by December 2025.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Nemvaleukin alfa Analytical Perspective by DelveInsight
This report provides a detailed market assessment of nemvaleukin alfa for ovarian cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.
The report provides the clinical trials information of nemvaleukin alfa for ovarian cancer covering trial interventions, trial conditions, trial status, start and completion dates.